Skip to content
Evevident
Original paper
2010NEJMPulmonary/Critical Care

ACURASYS

Neuromuscular blockers in early acute respiratory distress syndrome

RCTARDS

On this page

Overview

Early cisatracurium improved adjusted survival in severe early ARDS in ACURASYS.

Clinical takeaway

ACURASYS made early paralysis a serious option in severe ARDS, but its place changed after ROSE tested a modern high-PEEP/light-sedation strategy.

Key result

Adjusted 90-day mortality favored cisatracurium in severe early ARDS.

Practice impact

Consider short-course paralysis selectively for severe ventilator dyssynchrony or refractory hypoxemia, not routine ARDS care.

Evidence

Study design

Randomized, double-blind, placebo-controlled trial.

Enrollment

340

Follow-up

90 days.

Geography

France

Clinical question

Does early neuromuscular blockade improve outcomes in severe early ARDS?

Population

  • Mechanically ventilated adults with early severe ARDS.

Intervention

Cisatracurium infusion for 48 hours.

Comparator

Placebo infusion with deep sedation.

Primary outcome

90-day in-hospital mortality adjusted for baseline severity.

Early cisatracurium was associated with lower adjusted 90-day mortality in severe early ARDS.

Hazard ratio / 0.68 / CI 95% CI 0.48-0.98 / p=0.04

Key results

  • Adjusted 90-day mortality favored cisatracurium.
  • Barotrauma was reduced.
  • ICU-acquired paresis was not significantly increased in trial follow-up.

Harms

  • Deep sedation and paralysis can mask seizures, pain, awareness, and neurologic change.
  • ICU-acquired weakness remains a practical concern.

Clinical Use

When to cite

  • When considering short-course paralysis in severe early ARDS.

Practice impact

  • Prompted increased use of early neuromuscular blockade in severe ARDS before ROSE tempered routine use.

Applicability

  • Severe early ARDS with ventilator dyssynchrony or refractory hypoxemia despite lung-protective ventilation.

Limitations

  • Small single-country trial with deep sedation in both arms.
  • Modern sedation and PEEP approaches differ.

Common misinterpretations

  • Do not paralyze all ARDS patients automatically; ACURASYS is best interpreted alongside ROSE.

Related evidence

ARDSNet ARMA - ContextROSE - Contrasting Result

Citation

Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116. doi:10.1056/NEJMoa1005372